CONNECT WITH US
HealthTech

HealthTech

FDA approves new drug for advanced head and neck squamous cell carcinoma

Medical Xpress logo

Published on

Add as a preferred source on Google
FDA approves new drug for advanced head and neck squamous cell carcinoma

FDA approves new drug for advanced head and neck squamous cell carcinoma

This article has been reviewed according to Science X's editorial process and policies . Editors have highlighted the following attributes while ensuring the content's credibility:

The U.S. Food and Drug Administration has approved Janssen Biotech's Rybrevant Faspro (amivantamab and hyaluronidase-lpuj) for the treatment of adults with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC) whose disease has progressed during or after receipt of platinum-based chemotherapy and immunotherapy.

Rybrevant Faspro received accelerated approval, the first approval in 10 years of a drug for recurrent or metastatic HNSCC in patients with prior receipt of platinum-based chemotherapy. It is not indicated for treatment of oropharyngeal squamous cell carcinoma associated with human papillomavirus.

The approval is based on a trial of 102 patients with recurrent or metastatic HNSCC. Rybrevant Faspro had an overall response rate of 42% compared with 20% for currently approved therapies. Among patients who had a response to Rybrevant Faspro, 56% had a response lasting six months or longer.

"Today's approval represents a meaningful step forward for patients with HNSCC, a disease where treatment options have historically been limited and outcomes remain poor," Angelo De Claro, M.D., director of the FDA Oncology Center of Excellence, said in a statement.

Citation : FDA approves new drug for advanced head and neck squamous cell carcinoma (2026, November 17) retrieved 17 November 2026 from https://medicalxpress.com/news/2026-11-fda-drug-advanced-neck-squamous.html

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission.


Source link

Disclaimer

We strive to uphold the highest ethical standards in all of our reporting and coverage. We TheMorningPulse.fyi want to be transparent with our readers about any potential conflicts of interest that may arise in our work. It's possible that some of the investors we feature may have connections to other businesses, including competitors or companies we write about. However, we want to assure our readers that this will not have any impact on the integrity or impartiality of our reporting. We are committed to delivering accurate, unbiased news and information to our audience, and we will continue to uphold our ethics and principles in all of our work. Thank you for your trust and support.